{"id":"W3088603564","doi":"10.1016/j.annonc.2020.08.429","title":"327P Treatment sequencing in HR+/HER2- locally advanced or metastatic breast cancer: A real-world retrospective study in France, Germany, Italy and Spain","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Pfizer Pharmaceuticals; Novartis Pharmaceuticals Canada; Celldex Therapeutics; Astellas Pharma; Eisai; Chugai Pharmaceutical; Celltrion; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Celltrion Healthcare; Daiichi-Sankyo; Pfizer; Genomic Health","keywords":"Medicine; Fulvestrant; Internal medicine; Breast cancer; Metastatic breast cancer; Oncology; Cancer; Clinical trial; First line treatment; Chemotherapy; Tamoxifen","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003140135,0.0003045497,0.001299046,0.0002886711,0.00003144681,0.000005812887,0.0001097074,0.00006949596,0.0001303636],"category_scores_gemma":[0.00006629359,0.0002463898,0.00007101343,0.000887784,0.000194835,0.0001751572,0.00005778534,0.0002730656,0.000003620639],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001311673,"about_ca_system_score_gemma":0.00108985,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005285892,"about_ca_topic_score_gemma":0.02512548,"domain_scores_codex":[0.9978508,0.0002240565,0.0006600978,0.0005778144,0.0002326493,0.0004546177],"domain_scores_gemma":[0.9989184,0.00017971,0.0002916756,0.0002422906,0.0001746183,0.0001932847],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01499622,0.001950679,0.615226,0.0003145431,0.0009523029,0.003414711,0.02248003,0.002230187,0.007664138,0.0001613106,0.00003504382,0.3305748],"study_design_scores_gemma":[0.01675442,0.015783,0.9569337,0.0003965886,0.0001526447,0.0001220224,0.005677475,0.0007003437,0.0006934248,0.0003098413,0.002147424,0.000329072],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9877275,0.0011953,0.00004896401,0.008377798,0.00006048172,0.001585361,0.000072959,0.00004249721,0.0008891423],"genre_scores_gemma":[0.9947152,0.001492445,0.001063741,0.002029354,0.00008860339,0.000325326,0.000004138666,0.00004154251,0.000239611],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3417077,"threshold_uncertainty_score":0.9999988,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07734766725541938,"score_gpt":0.4071170968901116,"score_spread":0.3297694296346922,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}